Trials / Recruiting
RecruitingNCT07118215
A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin
A Phase 1, 3-part, Open-label Study to Evaluate the Effects of KarXT Administration on the Pharmacokinetics of Midazolam, Fexofenadine, and Digoxin in Healthy Adult Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effects of KarXT administration on the drug levels of midazolam, fexofenadine, and digoxin in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KarXT | Specified dose on specified days |
| DRUG | Midazolam | Specified dose on specified days |
| DRUG | Fexofenadine | Specified dose on specified days |
| DRUG | Digoxin | Specified dose on specified days |
Timeline
- Start date
- 2025-09-29
- Primary completion
- 2026-04-05
- Completion
- 2026-04-05
- First posted
- 2025-08-12
- Last updated
- 2026-03-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07118215. Inclusion in this directory is not an endorsement.